TYRUKO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TYRUKO (TYRUKO).
Tyr kinase inhibitor that selectively inhibits the activity of the enzyme tyrosine kinase, thereby blocking the phosphorylation and activation of downstream signaling pathways involved in cell proliferation and survival.
| Metabolism | Primarily metabolized by CYP3A4 isoenzyme in the liver. |
| Excretion | Primarily renal (70% as unchanged drug) and fecal (22% as metabolites). |
| Half-life | Terminal elimination half-life is 28 hours; approximately 5 days to steady-state. |
| Protein binding | 97% bound primarily to albumin. |
| Volume of Distribution | Approximately 5.1 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: 40% (fasting); subcutaneous: 100%. |
| Onset of Action | Oral: 1-2 months for measurable reduction in serum tryptase; subcutaneous: 2-4 weeks for symptom improvement. |
| Duration of Action | Sustained symptom control for 4-6 months after discontinuing therapy, consistent with mast cell turnover. |
TYRUKO (tirzepatide) subcutaneous injection: initial dose 2.5 mg once weekly for 4 weeks, then 5 mg once weekly; may increase in 2.5 mg increments after at least 4 weeks on current dose up to maximum 15 mg once weekly.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min). Not recommended in severe renal impairment (eGFR <30 mL/min) or end-stage renal disease due to lack of data. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use with caution. |
| Pediatric use | Safety and efficacy not established in pediatric patients (<18 years). No recommended dose. |
| Geriatric use | No specific dose adjustment recommended for elderly (≥65 years). Consider age-related renal function; monitor for volume depletion and gastrointestinal adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TYRUKO (TYRUKO).
| Breastfeeding | Contraindicated during breastfeeding due to potential for serious adverse reactions in breastfed infants. M/P ratio not determined. Excreted in animal milk. Discontinue nursing or drug. |
| Teratogenic Risk | Tyrosine kinase inhibitor. First trimester: potential teratogenicity based on animal studies (increased risk of fetal malformations, embryotoxic). Second/third trimester: may impair fetal growth and cause oligohydramnios; fetal toxicity including cardiopulmonary effects. Avoid in pregnancy unless benefit outweighs risk. |
■ FDA Black Box Warning
WARNING: Can cause life-threatening hypertension and fluid retention. Monitor blood pressure and fluid status closely.
| Serious Effects |
Hypersensitivity to drug or components; pregnancy (can cause fetal harm); severe hepatic impairment.
| Precautions | Hypertension, fluid retention, hepatotoxicity, QT prolongation, myelosuppression. Monitor hepatic function and electrolytes. |
Loading safety data…
| Fetal Monitoring |
| Monitor fetal growth via ultrasound; assess amniotic fluid volume. Maternal monitoring includes blood pressure, liver function, thyroid function, and proteinuria. Fetal echocardiography recommended if exposed. |
| Fertility Effects | May impair fertility in females (ovarian failure, menstrual irregularities) and males (spermatogenesis disruption). Effects may be reversible upon discontinuation. |